[
    [
        {
            "time": "",
            "original_text": "【开源医药】行业周报：关注集采下原料药企业业绩增量和医疗服务投资价值",
            "features": {
                "keywords": [
                    "开源医药",
                    "行业周报",
                    "集采",
                    "原料药",
                    "业绩增量",
                    "医疗服务",
                    "投资价值"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【开源医药】行业周报：关注集采下原料药企业业绩增量和医疗服务投资价值",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "兴业证券：医药板块业绩弹性逐步释放，关注半年报业绩高增长公司",
            "features": {
                "keywords": [
                    "兴业证券",
                    "医药板块",
                    "业绩弹性",
                    "逐步释放",
                    "半年报",
                    "高增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "证券时报-润灵全球2021生物医药行业ESG评级报告：较2020改善不明显",
            "features": {
                "keywords": [
                    "证券时报",
                    "润灵全球",
                    "生物医药",
                    "ESG评级",
                    "2021",
                    "改善不明显"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "证券时报-润灵全球2021生物医药行业ESG评级报告：较2020改善不明显",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]